aTyr Pharma Inc (LIFE)

3.23
0.04 1.20
NASDAQ : Health Care
Prev Close 3.27
Open 3.31
Day Low/High 3.22 / 3.42
52 Wk Low/High 2.48 / 21.00
Volume 32.82K
Avg Volume 227.70K
Exchange NASDAQ
Shares Outstanding 23.72M
Market Cap 78.27M
EPS -3.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

These 5 Stocks Are Breaking Out

These 5 Stocks Are Breaking Out

Here's a technical look at how to trade five stocks that are within range of triggering big breakouts.

5 Stocks With Big Insider Buying

5 Stocks With Big Insider Buying

Insiders at these companies have been scooping up shares of their own stock lately.

Here’s A Reason aTyr Pharma (LIFE) Stock is Rising Today

Here’s A Reason aTyr Pharma (LIFE) Stock is Rising Today

Shares of aTyr Pharma (LIFE) are climbing late Tuesday afternoon as BMO Capital began coverage of the stock with a ‘market perform’ rating and $8 price target.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

ATyr Provides Corporate Update And Outlook For 2016

ATyr Provides Corporate Update And Outlook For 2016

Data for Phase 1b/2 Clinical Trial of Resolaris in Adult FSHD Patients Expected at Approximately the End of First Quarter 2016

Oversold Conditions For aTyr Pharma (LIFE)

Oversold Conditions For aTyr Pharma (LIFE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Publication In Nature Demonstrates Physiocrine Genetic Mutation Disrupts A Key Signaling Pathway In Neuronal Biology

Publication In Nature Demonstrates Physiocrine Genetic Mutation Disrupts A Key Signaling Pathway In Neuronal Biology

aTyr Sponsored Research For New Target For Rare Hereditary Peripheral Neuropathies

ATyr Pharma Doses First Patient In Long-Term Safety Extension Study Of Resolaris™ For Treatment Of Adult Patients With FSHD

ATyr Pharma Doses First Patient In Long-Term Safety Extension Study Of Resolaris™ For Treatment Of Adult Patients With FSHD

Physiocrine-Based Therapy Harnesses Natural Immunomodulation Pathway to Address Rare Genetic Muscular Dystrophy